Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neurodegenerative tauopathies.

V M Lee1, M Goedert, J Q Trojanowski

  • 1Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA. vmylee@mail.med.upenn.edu

Annual Review of Neuroscience
|August 25, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: How Will Aducanumab Approval Impact AD Research?

The journal of prevention of Alzheimer's disease·2021
Same author

Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions.

Acta neuropathologica communications·2021
Same author

Pathological drivers of neurodegeneration in suspected non-Alzheimer's disease pathophysiology.

Alzheimer's research & therapy·2021
Same author

Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer's disease.

Neuropathology and applied neurobiology·2020
Same author

Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis.

Acta neuropathologica communications·2018
Same author

Connexin-43 and aquaporin-4 are markers of ageing-related tau astrogliopathy (ARTAG)-related astroglial response.

Neuropathology and applied neurobiology·2017
Same journal

Body-Brain Integration: The Lower Brainstem in Sleep-Wake Regulation.

Annual review of neuroscience·2026
Same journal

Planning in the Brain: It's Not What You Think It Is.

Annual review of neuroscience·2026
Same journal

The Emerging Neurobiology of Psychedelics: Critical Periods, Metaplasticity, and Extracellular Matrix Remodeling.

Annual review of neuroscience·2026
Same journal

Rethinking Predictive Processing.

Annual review of neuroscience·2026
Same journal

Path Integration in Alzheimer's Disease: Orientation, Movement, and Theta Rhythmicity.

Annual review of neuroscience·2026
Same journal

The Cellular and Circuit Basis of Temperature Sensation in <i>Drosophila</i>.

Annual review of neuroscience·2026
See all related articles

Neurodegenerative tauopathies, including Alzheimer's disease, involve abnormal tau protein aggregation. Genetic mutations and polymorphisms in the tau gene directly contribute to these diseases, impacting tau function and leading to distinct pathologies.

Area of Science:

  • Neuroscience
  • Genetics
  • Pathology

Background:

  • Alzheimer's disease (AD) is characterized by amyloid-beta plaques and tau tangles.
  • Neurodegenerative tauopathies, such as progressive supranuclear palsy and frontotemporal dementia, exhibit tau pathology without significant amyloid-beta deposits.
  • Genetic factors, including tau gene mutations and polymorphisms, are implicated in the etiology of these disorders.

Purpose of the Study:

  • To explore the direct link between tau gene abnormalities and the pathogenesis of neurodegenerative diseases.
  • To understand how different tau mutations may lead to distinct tau aggregate formations and disease phenotypes.
  • To highlight the role of tau pathology in both Alzheimer's disease and other tauopathies.

Main Methods:

  • Review of existing literature on tauopathies and genetic associations.

Related Experiment Videos

  • Analysis of the impact of tau gene mutations on tau protein function, aggregation, and splicing.
  • Discussion of the potential influence of additional genetic or epigenetic factors on disease manifestation.

    • Main Results:

    • Tau gene mutations are directly pathogenic, affecting tau function, promoting fibrillization, or altering gene splicing.
    • These mutations lead to the formation of biochemically and structurally diverse tau aggregates.
    • Phenotypic variability within families suggests additional factors influencing tauopathy presentation.

    Conclusions:

    • Tau abnormalities are central to the pathogenesis of neurodegenerative tauopathies, including Alzheimer's disease.
    • Understanding the mechanisms of tau aggregation and the influence of genetic factors is crucial for developing effective therapies.
    • Transgenic models are vital tools for further research and therapeutic development in tauopathies.